III期子宫内膜癌肿瘤分子检测的成本效果分析
本研究用马尔可夫决策模型比较III期子宫内膜癌患者接受肿瘤分子检测(TMT)与不检测(No TMT)的成本效果。TMT包括序贯POLE二代测序、错配修复免疫组化(IHC)和p53 IHC。结果显示TMT相比No TMT节约成本且效果相当,但与单独错配修复IHC相比,TMT每获得一个质量调整生命年(QALY)需花费182,798美元。
要点
- 在III期子宫内膜癌模型中,TMT相比No TMT节约成本且效果相当。
- 单因素敏感性分析显示TMT在所有参数范围内均保持节约成本。
- 以每QALY 100,000美元为支付意愿阈值,TMT在80%的概率敏感性分析迭代中更受青睐。
核心结论
- 在该III期子宫内膜癌患者模型中,TMT相比No TMT节约成本。
- 然而与单独错配修复IHC相比,TMT在经济上不利。
研究设计与样本
- 采用马尔可夫决策模型,比较III期子宫内膜癌的TMT策略与No TMT策略。
- TMT包括序贯POLE二代测序、错配修复免疫组化(IHC)和p53 IHC。
- POLE突变患者接受辅助放疗,所有其他患者包括对照接受辅助放化疗。
- 首次复发接受6周期卡铂和紫杉醇治疗;二次复发时错配修复缺陷患者接受帕博利珠单抗单药,其他患者接受帕博利珠单抗联合仑伐替尼。
- 进行敏感性分析以检验模型稳健性。
主要发现
- 与No TMT相比,TMT节约成本且效果相当。
- 单因素敏感性分析显示,TMT在所有参数范围内均保持节约成本。
- 在支付意愿阈值为每QALY 100,000美元时,概率敏感性分析中TMT在80%的迭代中更受青睐。
- 当TMT与单独错配修复IHC比较时,TMT每获得一个QALY需花费182,798美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard of care for adjuvant treatment of stage III endometrial cancer includes chemotherapy and radiation. In addition to stage, tumor molecular profiles may predict treatment outcomes, and prospective clinical trials are ongoing. However, tumor molecular testing is costly and time-consuming. Our objective was to evaluate the cost-effectiveness of tumor molecular testing in stage III endometrial cancer. METHODS: A Markov decision model compared two strategies for stage III endometrial cancer: Tumor Molecular Testing (TMT) versus No TMT. TMT included sequential POLE next generation sequencing, mismatch repair immunohistochemistry (IHC), and p53 IHC. POLE-mutated patients were assigned to adjuvant radiation therapy; all others including controls were assigned to adjuvant chemoradiation. First recurrences were treated with 6 cycles of carboplatin and paclitaxel. Second recurrences were treated with pembrolizumab alone for mismatch repair deficient patients and both pembrolizumab and lenvatinib for other patients. Sensitivity analyses were performed to test model robustness. RESULTS: Compared to No TMT, TMT was cost saving with equivalent effectiveness. On one-way sensitivity analysis, TMT remained cost saving over all parameter ranges. TMT was also favored on probabilistic sensitivity analysis in 80% of iterations at a willingness-to-pay threshold of $100,000/quality adjusted life-year (QALY) gained. However, when TMT was compared to mismatch repair IHC alone, TMT cost $182,798/QALY gained. CONCLUSIONS: In this model of patients with stage III endometrial cancer, TMT was cost saving compared to No TMT. However, when compared to mismatch repair IHC alone, TMT was economically unfavorable.
引用
- Orellana TJ, Kim H, Beriwal S, et al. Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer. Gynecol Oncol. 2023. PMID: 37105061. doi:10.1016/j.ygyno.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。